Enanta Pharmaceuticals (ENTA) Cash from Operations (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Cash from Operations data on file, last reported at 7156000.0 in Q1 2026.

• Quarterly Cash from Operations rose 46.95% year-over-year to 7156000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7838000.0 (up 85.87% YoY) and the FY2025 annual result came in at 19272000.0, up 75.53% from the prior year.
• Cash from Operations rose to 7156000.0 in Q1 2026, from 11699000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 17506000.0 in Q2 2025 to a low of 35641000.0 in Q4 2022.
• A 5-year average of 17150352.94 and a median of 15534000.0 in 2022 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations sank 476.0% — and 2025, when it surged 218.48%.
• Tracing ENTA's Cash from Operations over 5 years: stood at 35641000.0 in 2022, then rose by 29.89% to 24988000.0 in 2023, then jumped by 32.76% to 16801000.0 in 2024, then soared by 30.37% to 11699000.0 in 2025, then surged by 38.83% to 7156000.0 in 2026.
• The last three Cash from Operations figures came in at 7156000.0 (Q1 2026), 11699000.0 (Q4 2025), and 6489000.0 (Q3 2025), per Business Quant data.